InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 23 November 2023

TAI SHAN: This study is evaluating how safe, tolerable and effective a new drug is in people with relapsed or refractory B-cell Non-Hodgkin LymphomaA Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Clinical summary

Summary

Eligible participants will be assigned to cohorts that will receive increasing dosages of the study drug (called DZD8586). The starting dose of DZD8586 is 10mg once daily. If this is tolerated, subsequent cohorts will test increasing doses of DZD8586. 

Conditions

This trial is treating patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Cancer

Blood Cancers Haematological

Age

People18+

Phase

I/II

Trial Acronym

TAI SHAN

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Dizal Pharmaceuticals

Scientific Title

A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Eligibility

Inclusion

  1. All participants must provide a signed and dated written informed consent form prior to any study-specific procedures, sampling, and analysis.
  2. Male and female participants must be ≥ 18 years of age when signing the informed consent form.
  3. ECOG performance status score of 0 - 2 points and no disease deterioration in the past two weeks.
  4. Participants with relapsed or refractory B-NHL must be cytologically or histologically confirmed.
  5. Adequate bone marrow reserve (no blood transfusion within 7 days of the pre-enrollment visit, and no use of any stimulating factor or erythropoietin) and organ function.
  6. Participants should be able to follow the requirements of this study for medication use and follow-up.
  7. Female spouses (partners) of male participants who may become pregnant should use barrier contraception (such as condoms) during the participants' participation in the trial and within 6 months after the end of dosing. Male participants should also refrain from donating sperms during participation in the trial and within 6 months after the end of dosing.
  8. Female participants should use adequate contraception such as abstinence, tubal ligation, use of hormonal contraception with a known lower risk of drug-drug interaction [levonorgestrel intrauterine device (Mirena), medroxyprogesterone injection (Depo Provera)], copper-containing intrauterine device, and partner's vasectomy during the trial and within 3 months after the end of the trial.

Exclusion

  1. Have unresolved adverse drug reactions (except for alopecia) of higher than grade 1 (as defined by CTCAE v5.0) before the start of dosing in the study.
  2. A history of anticancer treatment within washout period as defined in the protocol.
  3. Participants with B-NHL other than CNSL who have central nervous system or intraocular lymphoma lesions.
  4. Participants with CNSL who have the following health conditions:

    1. Unable to cooperate with a lumbar puncture or cerebrospinal fluid test.
    2. Involvement of sites outside the CNS requiring systemic therapy.
    3. Participants with condition requiring systemic glucocorticoid therapy at a dose of > 8 mg/day (dexamethasone equivalent dose); or participants requiring immunosuppressant or biologic therapy.
  5. Active infectious diseases, including HBC, HCV, HIV, TB, etc.
  6. Abnormal heart and lung function.
  7. Refractory nausea and vomiting not well controlled by supportive care, chronic gastrointestinal disease, dysphagia, or previous surgical resection of bowel segments that may interfere with adequate drug absorption.
  8. Participants diagnosed with other malignancies apart from B-cell lymphoma within the past 5 years. However, participants may also be enrolled if the current evidence shows that the participant has been clinically cured and the investigator believes that the potential benefit of treatment with DZD8586 outweighs the potential risk.
  9. Participants with hypersensitivity to DZD8586 pharmaceutical excipients or other chemical analogs.
  10. Participants with serious or poorly controlled systemic diseases as judged by the investigator or other evidence, including poorly controlled hypertension and active bleeding disorders.
  11. Personnel involved in the planning and implementation of this study (only applicable to employees of the sponsor and study site).
  12. Female participants who are breastfeeding or pregnant.
  13. Participants who have taken DZD8586.
  14. Participants should not participate in the study if they are considered by the investigator to be unlikely to comply with study procedures, restrictions, and requirements.

Inclusion

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.